Pure Body Flow
MedCity News Healthcare technology news, life science current events
- Where Are the Biggest Opportunities in Women’s Cardiovascular Health?by Marissa Plescia on October 23, 2026 at 8:33 pm
MedTech Conference panelists cited inflammation research, listening to women, clinical trial representation and investment as priorities for women’s cardiovascular health. The post Where Are the Biggest Opportunities in Women’s Cardiovascular Health? appeared first on MedCity News.
- Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pillby Frank Vinluan on October 23, 2026 at 5:46 pm
Gilead Sciences is getting global rights to an experimental PepStar Therapeutics oral peptide designed to inhibit the IL-23 receptor to treat inflammatory bowel disease. It could compete against Johnson & Johnson’s Icotyde, an oral peptide that blocks the same target and is also in development for IBD. The post Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill appeared first on MedCity News.
- Why an Independent NP Practice Requires an Undergraduate Business Foundationby Octavia “Tavi” Schlueter on October 23, 2026 at 1:54 pm
Ultimately, while clinical training teaches nurses how to care for patients within a system, business education empowers them to design, protect, and scale the system. The post Why an Independent NP Practice Requires an Undergraduate Business Foundation appeared first on MedCity News.
- Amazon, Google and Other Major Employers Back CMS Prior Auth Effortby Marissa Plescia on October 22, 2026 at 9:52 pm
Amazon, Axon Enterprise, Google, Meta and Oracle backed expanding electronic prior authorization to self-funded employer health plans. The post Amazon, Google and Other Major Employers Back CMS Prior Auth Effort appeared first on MedCity News.
- Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisitionby Frank Vinluan on October 22, 2026 at 5:54 pm
Alcon’s Neurotech Pharmaceuticals acquisition brings the rare vision disorder cell therapy Encelto as well as the platform technology that developed it. Last year, Alcon acquired a majority stake in Aurion Biotech, a startup developing a corneal cell therapy. The post Alcon Expands Its Cell Therapy Ambitions With $550M Neurotech Pharma Acquisition appeared first on MedCity News.
- Why SDoH Programs Fall Short — and What It Takes to Make Them Workby David Wolf on October 22, 2026 at 1:21 pm
Throwing more money at SDoH programs isn’t going to magically fix them. Instead, plans should be focusing on building out these three specific capabilities that, together, can noticeably alter the playing field. The post Why SDoH Programs Fall Short — and What It Takes to Make Them Work appeared first on MedCity News.
- INVEST Digital Health Celebrates Healthcare Innovation in Texasby Stephanie Baum on October 22, 2026 at 11:30 am
In addition to a packed conference agenda and tours of the Pegasus Park healthcare and life science innovation hub in Dallas, INVEST Digital Health also includes an innovation showcase with novel health tech and medtech offerings as well as networking opportunities. The post INVEST Digital Health Celebrates Healthcare Innovation in Texas appeared first on MedCity News.
- Judi Health Launches Medicare Part D Plan for Employersby Marissa Plescia on October 21, 2026 at 10:18 pm
Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration. The post Judi Health Launches Medicare Part D Plan for Employers appeared first on MedCity News.
- GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cureby Frank Vinluan on October 21, 2026 at 6:38 pm
GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first on MedCity News.
- AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovationby Jenna Congdon on October 21, 2026 at 5:25 pm
As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice? The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and Support Responsible Innovation appeared first on MedCity News.
- Your Product Works — So Why Does It Still Fail in the Real World?by Mitchell Frye on October 21, 2026 at 1:34 pm
A patient’s automated risk score was reassuringly green. Pulling from a sparse medical record and infrequent acute visits, the model flagged him as low risk and routed him to the default, low-touch outpatient pathway — so why was the patient actively deteriorating? The post Your Product Works — So Why Does It Still Fail in the Real World? appeared first on MedCity News.
- FDA Official Believes GenAI-enabled Tools Will Need to Be Assessed Like a Physicianby Arundhati Parmar on October 20, 2026 at 10:23 pm
Rick Abramson, a radiologist by training and the director of FDA’s Digital Health Center of Excellence said, “We ended up putting out this idea that maybe these devices are starting to behave a little bit more like me as a physician than a heart valve or a defibrillator.” The post FDA Official Believes GenAI-enabled Tools Will Need to Be Assessed Like a Physician appeared first on MedCity News.
- Readily Secures $11M for Compliance Intelligence Platformby Marissa Plescia on October 20, 2026 at 9:00 pm
The Series A round was led by Define Ventures, with participation from Y Combinator and the California Health Care Foundation Innovation Fund. The post Readily Secures $11M for Compliance Intelligence Platform appeared first on MedCity News.
- GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancerby Frank Vinluan on October 20, 2026 at 7:21 pm
The GSK cancer immunotherapy Jemperli is now approved for treating advanced cases of rectal cancer harboring a particular genetic signature. It’s a label expansion for Jemperli, which was initially approved as a treatment for endometrial cancer. The post GSK Immunotherapy Gets Accelerated FDA Approval for Treating Rectal Cancer appeared first on MedCity News.
- A Radical Proposal to Preserve Cell and Gene Therapy Innovationby William Shrank on October 20, 2026 at 1:09 pm
Cell and gene therapies are amazing medical breakthroughs but if we don’t find ways to pay for them, the development pipeline will fail. The post A Radical Proposal to Preserve Cell and Gene Therapy Innovation appeared first on MedCity News.















